No, methimazole and propylthiouracil should NOT be used together
If a patient develops agranulocytosis or other serious side effects while taking either methimazole (MMI) or propylthiouracil (PTU), use of the other medication is absolutely contraindicated due to risk of cross-reactivity between the two medications 1.
Why These Drugs Are Never Combined
The evidence is unequivocal from major guidelines: these are alternative agents, not complementary therapies. The American Thyroid Association/American Association of Clinical Endocrinologists guidelines explicitly state that switching between these drugs is only appropriate for minor side effects, and even then, cross-reactivity remains a serious concern 1.
The Cross-Reactivity Problem
Recent case reports demonstrate dangerous cross-reactivity between MMI and PTU. A 2026 case documented recurrent pancreatitis when switching from MMI to PTU, suggesting immunological cross-reactions between these structurally similar thionamides 2. This reinforces the guideline prohibition against using the alternate drug after serious adverse events.
Clinical Algorithm for Antithyroid Drug Selection
Choose ONE drug based on clinical context:
Use Methimazole (preferred) when:
- Non-pregnant patients with Graves' disease 1
- Second and third trimester of pregnancy 3
- Pediatric patients (due to PTU hepatotoxicity risk) 3
- Once-daily dosing improves adherence 1
Use Propylthiouracil (limited indications) when:
- First trimester of pregnancy (MMI causes embryopathy: choanal/esophageal atresia, aplasia cutis) 1, 4
- Thyroid storm (though recent evidence questions this - see below)
- Minor allergic reactions to MMI when radioiodine/surgery refused 1
What To Do With Side Effects
Minor reactions (rash, urticaria):
- Manage with antihistamines while continuing the same drug 1
- If persistent, switch to the other thionamide (not add) 1
- Consider radioiodine or surgery as definitive alternatives 1
Major reactions (agranulocytosis, severe hepatotoxicity, vasculitis):
- Immediately discontinue the offending drug
- Never use the other thionamide - cross-reactivity risk is too high 1
- Proceed directly to radioiodine ablation or thyroidectomy 1
Important Safety Distinctions
PTU carries greater hepatotoxicity risk:
- Can cause fulminant hepatic necrosis requiring transplantation 1
- FDA black box warning after 32 cases of serious liver injury 1
- Meta-analysis confirms higher odds of liver injury (OR 2.40) and elevated transaminases (OR 3.96) versus MMI 5
MMI carries first-trimester teratogenicity:
- Specific embryopathy pattern well-documented 3
- Meta-analysis shows higher congenital anomaly risk versus PTU in pregnancy (OR 0.80 for PTU) 4
Both drugs cause agranulocytosis in dose-dependent fashion:
- MMI: 0.13% at 10mg to 0.47% at 30mg daily 6
- PTU: 0.33% at 150mg to 0.81% at 300mg daily 6
- At equivalent potency doses, PTU has 4-fold higher agranulocytosis risk 6
Common Pitfall to Avoid
Do not confuse "switching" with "combining." The guidelines discuss switching from one drug to another as monotherapy - never concurrent use. The only combination therapy mentioned is "block and replace" (high-dose antithyroid drug PLUS levothyroxine), which uses a single antithyroid agent and is generally not recommended due to higher side effect rates 1.
Thyroid Storm Exception May Be Outdated
While older guidelines recommend PTU for thyroid storm 1, a 2023 multicenter study of 1,383 critically ill patients found no mortality difference between PTU and MMI (adjusted risk difference 0.6%, P=0.64), suggesting this recommendation may warrant reevaluation 7.